Vitamin K2

From Wikipedia, the free encyclopedia
  (Redirected from Menaquinone)
Jump to: navigation, search

Vitamin K2 or menaquinone (/ˌmɛnəˈkwɪnn/) has nine related compounds, generally subdivided into the short-chain menaquinones (with MK-4 as the most important member) and the long-chain menaquinones, of which MK-7, MK-8 and MK-9 are nutritionally the most recognized.

Description[edit]

Vitamin K2, the main storage form in animals, has several subtypes, which differ in isoprenoid chain length. These vitamin K2 homologues are called menaquinones, and are characterized by the number of isoprenoid residues in their side chains. Menaquinones are abbreviated MK-n, where M stands for menaquinone, the K stands for vitamin K, and the n represents the number of isoprenoid side chain residues. For example, menaquinone-4 (abbreviated MK-4) has four isoprene residues in its side chain. Menaquinone-4 (also known as menatetrenone from its four isoprene residues) is the most common type of vitamin K2 in animal products since MK-4 is normally synthesized from vitamin K1 in certain animal tissues (arterial walls, pancreas, and testes) by replacement of the phytyl tail with an unsaturated geranylgeranyl tail containing four isoprene units, thus yielding menaquinone-4. This homolog of vitamin K2 may have enzyme functions distinct from those of vitamin K1.

Menaquinone-7 is different from MK-4 in that it is not produced by human tissue. MK-7 may be converted from phylloquinone (K1) in the colon by Escherichia coli bacteria.[1] However, bacterially derived menaquinones (MK-7) appear to contribute minimally to overall vitamin K status.[2][3] MK-4 and MK-7 are both found in the United States in dietary supplements for bone health.

The U.S. Food and Drug Administration (FDA) has not approved any form of vitamin K for the prevention or treatment of osteoporosis; however, MK-4 has been shown to decrease the incidence of fractures up to 87%.[4] MK-4 (45 mg daily) has been approved by the Ministry of Health in Japan since 1995 for the prevention and treatment of osteoporosis.[5]

All K vitamins are similar in structure: they share a "quinone" ring, but differ in the length and degree of saturation of the carbon tail and the number of "side chains".[6][full citation needed] The number of side chains is indicated in the name of the particular menaquinone (e.g., MK-4 means that four molecular units – called isoprene units – are attached to the carbon tail) and this influences the transport to different target tissues.

Vitamin K structures. MK-4 and MK-7 are both subtypes of K2.

Mechanism of action[edit]

The mechanism of action of vitamin K2 is similar to vitamin K1. Traditionally, K vitamins were recognized as the factor required for coagulation, but the functions performed by this vitamin group were revealed to be much more complex. K vitamins play an essential role as cofactor for the enzyme γ-glutamyl carboxylase, which is involved in vitamin K-dependent carboxylation of the gla domain in "Gla proteins" (i.e., in conversion of peptide-bound glutamic acid (Glu) to γ-carboxy glutamic acid (Gla) in these proteins).

Carboxylation reaction – the Vitamin K cycle

Carboxylation of these vitamin K-dependent Gla-proteins, besides being essential for the function of the protein, is also an important vitamin recovery mechanism since it serves as a recycling pathway to recover vitamin K from its epoxide metabolite (KO) for reuse in carboxylation.

Several human Gla-containing proteins synthesized in several different types of tissues have been discovered:

  • Coagulation factors (II, VII, IX, X), as well as anticoagulation proteins (C, S, Z). These Gla-proteins are synthesized in the liver and play an important role in blood homeo-stasis.
  • Osteocalcin. This non-collagenous protein is secreted by osteoblasts and plays an essential role in the formation of mineral in bone.
  • Matrix gla protein (MGP). This calcification inhibitory protein is found in numerous body tissues, but its role is most pronounced in cartilage and in arterial vessel walls.
  • Growth arrest-specific protein 6 (GAS6). GAS6 is secreted by leucocytes and endothelial cells in response to injury and helps in cell survival, proliferation, migration, and adhesion.
  • Proline-rich Gla-proteins (PRGP), transmembrane Gla-proteins (TMG), Gla-rich protein (GRP) and periostin; whose precise functions are still unexplored.

Health effects[edit]

Vitamin K2 has only begun to be studied, and the few studies on humans suffer from either a small number of test subjects or that the study has yet to be reproduced by an independent team. The possible health benefits which those studies have suggested may be worth further investigation are mostly related to bone strength and arterial health (reducing calcification or even decalcifying, with a possible reduction in blood pressure).

Absorption profile of different K vitamins[edit]

Vitamin K is absorbed along with dietary fat from the small intestine and transported by chylomicrons in the circulation. Most of vitamin K1 is carried by triacylglycerol-rich lipoproteins (TRL) and rapidly cleared by the liver; only a small amount is released into the circulation and carried by LDL and HDL. MK-4 is carried by the same lipoproteins (TRL, LDL, and HDL) and cleared fast as well. The long-chain menaquinones are absorbed in the same way as vitamin K1 and MK-4, but are efficiently redistributed by the liver in predominantly LDL (VLDL). Since LDL has a long half life in the circulation, these menaquinones can circulate for extended times resulting in higher bioavailability for extra-hepatic tissues as compared to vitamin K1 and MK-4. Accumulation of vitamin K in extra-hepatic tissues has direct relevance to vitamin K functions not related to hemostasis.[7]

Dietary intake in humans[edit]

The European Food Safety Authority (EU) and the US Institute of Medicine, on reviewing existing evidence, have decided there is insufficient evidence to publish a dietary reference value for vitamin K or for K2. They have, however, published an adequate intake (AI) for vitamin K, but no value specifically for K2.

Parts of the scientific literature, dating back to 1998, suggest that the AI values are based only on the hepatic requirements (i.e. related to the liver).[8][9] This hypothesis is supported by the fact that the majority of the Western population exhibits a substantial fraction of undercarboxylated extra-hepatic proteins.[citation needed] Thus, complete activation of coagulation factors is satisfied, but there does not seem to be enough vitamin K2 for the carboxylation of osteocalcin in bone and MGP in the vascular system.[10][11]

There is no known toxicity associated with high doses of menaquinones (vitamin K2). Unlike the other fat-soluble vitamins, vitamin K is not stored in any significant quantity in the liver; therefore the toxic level is not a described problem. All data available as of 2017 demonstrate that vitamin K has no adverse effects in healthy subjects. The recommendations for the daily intake of vitamin K, as issued recently by the US Institute of Medicine, also acknowledge the wide safety margin of vitamin K: "A search of the literature revealed no evidence of toxicity associated with the intake of either K1 or K2". Animal models involving rats, if generalisable to humans, show that MK-7 is well-tolerated.[12]

Dietary sources[edit]

Apart from animal livers, the richest dietary source of long-chain menaquinones are fermented foods (from bacteria not moulds or yeasts) typically represented by cheeses (MK-8, MK-9) in Western diets and nattō (MK-7) in Japan. Food frequency questionnaire-derived estimates of relative intakes in the Netherlands suggest that about 90% of total vitamin K intakes are provided by K1, about 7.5% by MK-5 through MK-9 and about 2.5% by MK-4. Most food assays measure only fully unsaturated menaquinones; accordingly, cheeses have been found to contain MK-8 at 10–20 μg per 100 g and MK-9 at 35–55 μg per 100 g.[7]

Vitamin K2 is preferred by the extrahepatic tissues (bone, cartilage, vasculature) and this may be produced as MK-4 by the animal from K1, or may be of bacterial origin (MK-7, MK-9, and other MKs). Discussion is ongoing as to what extent K2 produced by human intestinal bacteria contributes to daily vitamin K2 needs.

Menaquinone-4 is synthesized by animal tissues and is found in meat, eggs, and dairy products.[13] The MK-4 form of K2 is often found in relatively small quantities in meat and eggs. There are no substantial differences in MK-4 levels between wild game, free-range animals, and factory farm animals.[14]

Menaquinone-7 is synthesized by bacteria during fermentation and is found in fermented soybeans (nattō), and in most fermented cheeses.[15] In nattō, none of the vitamin K is from menaquinone-4, and in cheese only 2–7% is.[16] The richest source of natural K2 is the traditional Japanese dish natto[17] made of fermented soybeans and Bacillus subtilis, which provides an unusually rich source of K2 as long-chain MK-7: its consumption in Northern Japan has been linked to significant improvement in vitamin K status and bone health in many studies. The intense smell and strong taste, however, make this soya food a less attractive source of K2 for Westerners' tastes. Supplement food companies sell nattō extract, standardized for K2 content, in capsules. It is not known whether B. subtilis will produce K2 with other legumes (chickpeas, beans, lentils).

Food Vitamin K2 (μg per 100 g) Proportion of compounds
Nattō, cooked 1,034.0[14] 0% MK-4, 1% MK-5, 1% MK-6, 90% MK-7, 8% MK-8
Goose liver pâté 369.0[14] 100% MK-4
Australian emu oil 360[18]
Hard cheeses 76.3[14] 6% MK-4, 2% MK-5, 1% MK-6, 2% MK-7, 22% MK-8, 67% MK-9
Soft cheeses 56.5[14] 6.5% MK-4, 0.5% MK-5, 1% MK-6, 2% MK-7, 20% MK-8, 70% MK-9
Egg yolk (Netherlands) 32.1[14] 98% MK-4, 2% MK-6
Goose leg 31.0[14] 100% MK-4
Grass-fed ghee and butter oil 19.6–43.1
average 29.9[19]
Curd cheeses 24.8[14] 2.6% MK-4, 0.4% MK-5, 1% MK-6, 1% MK-7, 20% MK-8, 75% MK-9
Egg yolk (U.S.) 15.5[20] 100% MK-4
Butter 15.0[14] 100% MK-4
Chicken liver (raw) 14.1[20] 100% MK-4
Chicken liver (pan-fried) 12.6[20] 100% MK-4
Cheddar cheese (U.S.) 10.2[20] 6% MK-4, 94% other MK
Meat franks 9.8[20] 100% MK-4
Salami 9.0[14] 100% MK-4
Chicken breast 8.9[14] 100% MK-4
Chicken leg 8.5[14] 100% MK-4
Ground beef (medium fat) 8.1[20] 100% MK-4
Luncheon meat 7.7[14] 100% MK-4
Chicken liver (braised) 6.7[20] 100% MK-4
Minced meat 6.7[14] 100% MK-4
Calf's liver (pan-fried) 6.0[20] 100% MK-4
Hot dog 5.7[20] 100% MK-4
Bacon 5.6[20] 100% MK-4
Whipping cream 5.4[14] 100% MK-4
Sauerkraut 4.8[14] 8% MK-4, 17% MK-5, 31% MK-6, 4% MK-7, 17% MK-8, 23% MK-9
Pork steak 3.7[14] 57% MK-4, 13% MK-7, 30% MK-8
Duck breast 3.6[14] 100% MK-4
Buttermilk 2.5[14] 8% MK-4, 4% MK-5, 4% MK-6, 4% MK-7, 24% MK-8, 56% MK-9
Plaice 2.2[14] 9% MK-4, 14% MK-6, 4% MK-7, 73% MK-8
Eel 2.2[14] 77% MK-4, 5% MK-6, 18% MK-7
Fermented cod liver oil 1.8[19] 69% MK-4, 18% MK-6, 6% MK-8, 7% MK-9
Chocolate 1.5[14] 100% MK-4
Beef 1.1[14] 100% MK-4
Buckwheat bread 1.1[14] 100% MK-7
Whole milk yogurt 0.9[14] 67% MK-4, 11% MK-5, 22% MK-8
Whole milk 0.9[14] 89% MK-4, 11% MK-5
Egg white 0.9[14] 100% MK-4
Venison back 0.7[14] 100% MK-4
Salmon 0.5[14] 100% MK-4
Cow's liver (pan-fried) 0.4[20] 100% MK-4
Mackerel 0.4[14] 100% MK-4
Pork liver 0.3[14] 100% MK-4
Rabbit leg 0.1[14] 100% MK-4
Skimmed milk yogurt 0.1[14] 100% MK-8

Prawns, herring, kale, spinach, broccoli, green peas, bananas, apples, oranges, margarine, corn oil, sunflower oil, olive oil, rye bread, wheat bread, sourdough bread, and tea contain vitamin K1 but not vitamin K2. Skimmed milk and coffee do not contain any vitamin K.[14]

Anticoagulants and K2 supplementation[edit]

Recent studies found a clear association between long-term anticoagulant treatment (OAC) and reduced bone quality due to reduction of active osteocalcin. OAC might lead to an increased incidence of fractures, reduced bone mineral density or content, osteopenia, and increased serum levels of undercarboxylated osteocalcin.[21] Bone mineral density was significantly lower in stroke patients with long-term warfarin treatment compared to untreated patients and osteopenia was probably an effect of warfarin-interference with vitamin K recycling.[22]

Furthermore, OAC is often linked to undesired soft-tissue calcification in both children and adults.[23][24] This process has been shown to be dependent upon the action of K vitamins. Vitamin K deficiency results in undercarboxylation of MGP. Vascular calcification was shown to appear in warfarin-treated experimental animals within two weeks.[25] Also in humans on OAC treatment, two-fold more arterial calcification was found as compared to patients not receiving vitamin K antagonists.[26][27] Among consequences of anticoagulant treatment: increased aortic wall stiffness, coronary insufficiency, ischemia, and even heart failure. Arterial calcification might also contribute to systolic hypertension and ventricular hypertrophy.[28][29] Coumarins, by interfering with vitamin K metabolism, might also lead to an excessive calcification of cartilage and tracheobronchial arteries.

Anticoagulant therapy is usually instituted to avoid life-threatening diseases and a high vitamin K intake interferes with the anticoagulant effect. Patients on warfarin (Coumadin) treatment, or treatment with other vitamin K antagonist drugs, are therefore advised not to consume diets rich in K vitamins. However, the latest research proposed to combine vitamins K with OAC to stabilize the INR (International normalized ratio, a laboratory test measure of blood coagulation).

Individuals taking anticoagulant medications, such as warfarin (coumarins), should consult their doctor before taking vitamin K2.

References[edit]

  1. ^ Vermeer, C.; Braam, L. (2001). "Role of K vitamins in the regulation of tissue calcification". Journal of bone and mineral metabolism. 19 (4): 201–206. PMID 11448011. doi:10.1007/s007740170021. 
  2. ^ Suttie, J. W. (1995). "The importance of menaquinones in human nutrition". Annual Review of Nutrition. 15: 399–417. PMID 8527227. doi:10.1146/annurev.nu.15.070195.002151. 
  3. ^ Weber, P. (2001). "Vitamin K and bone health". Nutrition. 17 (10): 880–887. PMID 11684396. doi:10.1016/S0899-9007(01)00709-2. 
  4. ^ Sato, Y.; Kanoko, T.; Satoh, K.; Iwamoto, J. (2005). "Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease". Bone. 36 (1): 61–68. PMID 15664003. doi:10.1016/j.bone.2004.09.018. 
  5. ^ Iwamoto, I.; Kosha, S.; Noguchi, S. (1999). "A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women a comparative study with vitamin D3 and estrogen-progestin therapy". Maturitas. 31 (2): 161–164. PMID 10227010. doi:10.1016/S0378-5122(98)00114-5. 
  6. ^ Shearer, M. J. (2003). Physiology. Elsevier Sciences. pp. 6039–6045. 
  7. ^ a b Shearer, Martin J.; Newman, Paul (2008). "Metabolism and cell biology of vitamin K". Thrombosis and Haemostasis. 100 (4). ISSN 0340-6245. doi:10.1160/th08-03-0147. 
  8. ^ Booth, S. L.; Suttie, J. W. (1998). "Dietary intake and adequacy of K vitamins". J. Nutr. 128 (5): 785–788. 
  9. ^ Schurgers, L. J.; Vermeer, C. (2002). "Differential lipoprotein transport pathways of K-vitamins in healthy subjects". Biochim. Biophys. Acta. 1570 (1): 27–32. doi:10.1016/s0304-4165(02)00147-2. 
  10. ^ Hofbauer, L. C.; Brueck, C. C.; Shanahan, C. M.; Schoppet, M.; Dobnig, H. (2007). "Vascular calcification and osteoporosis – from clinical observation towards molecular understanding". Osteoporos Int. 18 (3): 251–259. 
  11. ^ Plantalech, L.; Guillaumont, M.; Vergnaud, P.; Leclercq, M.; Delmas, P. D. (1991). "Impairment of gamma-carboxylation of circulating osteocalcin (bone Gla protein) in elderly women". J. Bone Miner. Res. 6 (11): 1211–1216. 
  12. ^ Pucaj, K.; Rasmussen, H.; Møller, M.; Preston, T. "Safety and toxicological evaluation of a synthetic vitamin K2, menaquinone-7". Toxicol. Mech. Methods. 21: 520–532. PMC 3172146Freely accessible. PMID 21781006. doi:10.3109/15376516.2011.568983. 
  13. ^ Elder, S. J.; Haytowitz, D. B.; Howe, J.; Peterson, J. W.; Booth, S. L. (2006). "Vitamin K contents of meat, dairy, and fast food in the U.S. Diet". J. Agric. Food Chem. 54 (2): 463–467. PMID 16417305. doi:10.1021/jf052400h. 
  14. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah Schurgers, Leon J.; Vermeer, Cees (November 2000). "Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations". Haemostasis. 30 (6): 298–307. doi:10.1159/000054147. Retrieved 12 October 2016. 
  15. ^ Tsukamoto, Y.; Ichise, H.; Kakuda, H.; Yamaguchi, M. (2000). "Intake of fermented soybean (natto) increases circulating vitamin K2 (menaquinone-7) and gamma-carboxylated osteocalcin concentration in normal individuals". J. Bone Miner. Metab. 18 (4): 216–222. PMID 10874601. doi:10.1007/s007740070023. 
  16. ^ "On the Trail of the Elusive X-Factor: Vitamin K2 Revealed". 
  17. ^ Kaneki, M.; Hodges, S. J.; Hosoi, T.; Fujiwara, S.; Lyons, A.; Crean, S. J.; Ishida, N.; Nakagawa, M.; Takechi, M.; Sano, Y.; Mizuno, Y.; Hoshino, S.; Miyao, M.; Inoue, S.; Horiki, K.; Shiraki, M.; Ouchi, Y.; Orimo, H. (2001). "Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of K vitamins. 2: possible implications for hip-fracture risk". Nutrition. 17 (4): 315–321. 
  18. ^ "Factsheet – Vitamin K2" (PDF). emutracks.com.au. 
  19. ^ a b "Hook Line and Stinker" (PDF). 
  20. ^ a b c d e f g h i j k Rhéaume-Bleue, Kate (August 27, 2013). Vitamin K2 and the Calcium Paradox: How a Little-Known Vitamin Could Save Your Life. Harper. pp. 66–67. ISBN 0062320041. 
  21. ^ Caraballo, P.J.; Gabriel, S.E.; Castro, M.R.; Atkinson, E.J.; Melton, L.J., III (1999). "Changes in bone density after exposure to oral anticoagulants: a meta-analysis". Osteoporos Int. 9 (5): 441–448. 
  22. ^ Sato, Y.; Honda, Y.; Kunoh, H.; Oizumi, K. (1997). "Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation". Stroke. 28 (12): 2390–2394. doi:10.1161/01.str.28.12.2390. 
  23. ^ Barnes, C.; Newall, F.; Ignjatovic, V.; Wong, P.; Cameron, F.; Jones, G.; P., Monagle (2005). "Reduced bone density in children on long-term warfarin". Pediatr. Res. 57 (4): 578–581. doi:10.1203/01.pdr.0000155943.07244.04. 
  24. ^ Hawkins, D.; Evans, J. (2005). "Minimising the risk of heparin-induced osteoporosis during pregnancy". Expert Opin. Drug Saf. 4 (3): 583–590. doi:10.1517/14740338.4.3.583. 
  25. ^ Price, P. A.; Faus, S. A.; Williamson, M. K. (1998). "Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves". Arterioscler. Thromb. Vasc. Biol. 18 (9): 1400–1407. doi:10.1161/01.atv.18.9.1400. 
  26. ^ Schurgers, L. J.; Aebert, H.; Vermeer, C.; Bültmann, B.; Janzen, J. (2004). "Oral anticoagulant treatment: friend or foe in cardiovascular disease?". Blood. 104 (10): 3231–3232. doi:10.1182/blood-2004-04-1277. 
  27. ^ Koos, R.; Mahnken, A. H.; Mühlenbruch, G.; Brandenburg, V.; Pflueger, B.; Wildberger, J. E.; Kühl, H. P. (2005). "Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography". Am. J. Cardiol. 96 (6): 747–749. doi:10.1016/j.amjcard.2005.05.014. 
  28. ^ Zieman, S. J.; Melenovsky, V.; Kass, D. A. (2005). "Mechanisms, pathophysiology, and therapy of arterial stiffness". Arterioscler. Thromb. Vasc. Biol. 25 (5): 932–943. 
  29. ^ Raggi, P.; Shaw, L. J.; Berman, D. S.; Callister, T. Q. (2004). "Prognostic value of coronary artery calcium screening in subjects with and without diabetes". J. Am. Coll. Cardiol. 43 (9): 1663–1669. doi:10.1016/j.jacc.2003.09.068.